Page last updated: 2024-11-04

bw 306u

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hydroxybupropion: active metabolite of bupropion; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID446
CHEMBL ID3544616
CHEBI ID166487
SCHEMBL ID1226857
MeSH IDM0140048

Synonyms (28)

Synonym
82793-84-8
CHEBI:166487
92264-81-8
1-(3-chlorophenyl)-2-[(1-hydroxy-2-methylpropan-2-yl)amino]propan-1-one
hydroxybupropion
AKOAEVOSDHIVFX-UHFFFAOYSA-N
2-(1-hydroxy-2-methylpropan-2-ylamino)-1-(3-chlorophenyl)propan-1-one
SCHEMBL1226857
hydroxybupropione
unii-v94f513635
v94f513635 ,
6-hydroxybupropion
bw-306u
hydroxybupropion, (+/-)-
1-propanone, 1-(3-chlorophenyl)-2-((2-hydroxy-1,1-dimethylethyl)amino)-
CHEMBL3544616
1-(3-chlorophenyl)-2-[(2-hydroxy-1,1-dimethylethyl)amino]-1-propanone
bdbm224811
us9333197, hydroxybupropion
1-(3-chlorophenyl)-2-(1-hydroxy-2-methylpropan-2-ylamino)propan-1-one
HY-100637
CS-0019871
Q18206601
(+/-)-hydroxybupropion
DTXSID101002894
B0094-467887
AKOS040733401
hydroxybupropion, 1mg/ml in acetonitrile

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Recently, the chirality of bupropion has received significant attention in the delineation of stereoselective pharmacokinetic (PK) and disposition data."( Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion.
Dash, RP; Rais, R; Srinivas, NR, 2018
)
0.48
" The concentration-time curve (AUC(0→96)), maximum plasma concentration (Cmax), and terminal half-life (t1/2) values of BUP in CYP2B6*1/*4 were lower than those of CYP2B6*1/*1."( Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects.
Dang, H; Ma, H; Ma, Y; Wei, S; Yang, X; Zhang, H; Zhang, W; Zhang, Y, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" Alternatively, a curvilinear dose-response relationship may exist for bupropion metabolites."( Bupropion in depression. II. The role of metabolites in clinical outcome.
De Vane, CL; Golden, RN; Laizure, SC; Potter, WZ; Rudorfer, MV; Sherer, MA, 1988
)
0.27
" However, therapeutic efficacy and treatment success is often variable, requiring changes in dosing regimens or drug selection."( The development and validation of a turbulent flow-liquid chromatography-tandem mass spectrometric method for the simultaneous quantification of citalopram, sertraline, bupropion and hydroxybupropion in serum.
Clarke, W; Jannetto, PJ; Johnson-Davis, KL; Langman, LJ; Marzinke, MA; Moskowitz, J; Petrides, AK, 2014
)
0.4
" Human subjects were dosed with a single oral dose of 75 mg of an immediate release bupropion HCl tablet."( Identification of non-reported bupropion metabolites in human plasma.
Babiskin, A; Connarn, JN; Ellingrod, VL; Harrington, G; Kamali, M; Kelly, M; Luo, R; McInnis, M; Sun, D; Windak, J; Zhang, X, 2016
)
0.43
" The findings of this study suggest opportunities to further study precision dosing strategies for bupropion therapy based on CYP2B6 genotype."( Association of CYP2B6 genetic polymorphisms with bupropion and hydroxybupropion exposure: A systematic review and meta-analysis.
Bishop, JR; Eum, S; Lee, AM; Sayre, F; Stingl, JC, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.13)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's26 (81.25)24.3611
2020's5 (15.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.74 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (15.63%)5.53%
Reviews3 (9.38%)6.00%
Case Studies3 (9.38%)4.05%
Observational0 (0.00%)0.25%
Other21 (65.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]